Plasma Urotensin II levels in children and adolescents with chronic kidney disease: a single-centre study
© The Author(s). 2017
Received: 7 October 2015
Accepted: 24 March 2017
Published: 31 March 2017
Increased plasma Urotensin II (UII) levels have been found in adults with renal diseases. Studies in children are scarce. The objective of the study is to estimate plasma UII levels in subjects with chronic kidney disease (CKD) stages 3 to 5 and renal transplant recipients (RTR). In addition, the correlation of UII with anthropometric features and biochemical parameters was assessed.
Fifty-four subjects, aged 3 to 20 years old, 23 with CKD, 13 with end-stage kidney disease (ESKD) undergoing hemodialysis (HD) and 18 RTR were enrolled. A detailed clinical evaluation was performed. Biochemical parameters of renal and liver function were measured. Plasma UII levels were measured in all patients and in 117 healthy controls, using a high sensitive enzyme immunoassay (EIA) kit. All data were analyzed using STATA™ (Version 10.1).
Median UII and mean log-transformed UII levels were significantly higher in CKD and RTR patients compared to healthy subjects (p < 0.001). HD patients had higher but not statistically significant UII and log-UII levels than controls. UII levels increased significantly at the end of the HD session and were higher than controls and in line to those of other patients. The geometric scores of UII in HD (before dialysis), CKD and RTR patients increased respectively by 42, 136 and 164% in comparison with controls. Metabolic acidosis was associated with statistical significant change in log-UII levels (p = 0.001). Patients with metabolic acidosis had an increase in UII concentration by 76% compared to those without acidosis.
Children and adolescents with CKD, particularly those who are not on HD and RTR, have significantly higher levels of UII than healthy subjects. UII levels increase significantly at the end of the HD session. The presence of metabolic acidosis affects significantly plasma UII levels.
KeywordsRenal transplantation End-stage kidney disease Hemodialysis Renal failure Acidosis
Urotensin II (UII) is the most potent vasoconstrictor peptide in humans. It has also been reported to have a vasodilatory effect on small arteries of rats as well as on resistance arteries of humans [1–3]. It is synthesized mainly in the kidney, but also in non-renal tissues such as the heart, liver, pancreas and adrenal glands . The high levels of plasma UII in surgically anephric patients is a strong indication of extrarenal production .
Increased plasma UII levels have been found in many pathological conditions such as hypertension, cirrhosis, congestive heart failure and renal failure, but the role of UII in human diseases, including renal disease, is still controversial [6–14]. Initial evidence suggested that UII contributes to the development of cardiovascular diseases as well as renal dysfunction, however in the last decade many studies have shown a possible cardioprotective role of high UII levels in patients with ischemic heart disease and chronic kidney disease (CKD) [11, 15, 16]. Furthermore, low UII levels have been associated with cardiovascular events and death in adults with CKD [17, 18].
There is limited information on UII levels in children. There are few reports on UII levels in children and adolescents with pulmonary hypertension, portal hypertension, congenital heart disease and nephrotic syndrome [19–23].
To our knowledge this is the first study of plasma UII levels in children and adolescents with CKD of stages 3–5, ESKD on dialysis and renal transplantation.
The aim of the present study was to evaluate prospectively plasma UII concentration in the above pediatric population; its association with management options (dialysis or no dialysis, renal transplantation) and its correlation with anthropometric features, hemodynamic and biochemical parameters.
In this single - centre prospective study, fifty-four Caucasian children and adolescents (33 boys, 21 girls), aged 3 to 20 years old, twenty-three with CKD stages 3–5, thirteen with ESKD who were on regular dialysis treatment and eighteen RTR, were enrolled. The mean age had no statistically significant difference between the three groups (p 0.424). The underlying causes of chronic kidney disease include: Hypodysplasia ± reflux nephropathy (n = 23), obstructive uropathy (n = 6), glomerulonephritis (n = 6), congenital kidney and urinary tract anomalies (CAKUT, n = 5), cystic kidney disease (n = 3), congenital nephrotic syndrome (n = 3), hereditary nephropathy (n = 3), hemolytic uremic syndrome (HUS, n = 2), miscellaneous(n = 1), unknown (n = 2). One hundred and seventeen age-matched (p = 0.242) healthy children and adolescents comprised the control group. Patients and controls were recruited from the Department of Nephrology and from the 2nd Department of Pediatrics of Athens University of the “P. & A. Kyriakou” Children’s’ Hospital respectively. The study was conducted from May 2012 to February 2014 and was approved by the Hospital’s Ethics Committee prior to its initiation. All participants’ parents or legal guardians were required to complete a consent form. Parents of only one child with CKD refused to participate in the study. The following exclusive criteria were mandatory for the patients group: children below 3 years of age, CKD stages 1 and 2, duration of dialysis and transplantation less than 2 and 6 months respectively and those with co-occurrence of hepatic, pulmonary or congenital heart disease.
Definition and classification of CKD
For the definition of CKD we used the criteria recommended by Kidney Disease Quality Outcome Initiative (K/DOQI) . CKD staging was based on the estimated Glomerular Filtration Rate (eGFR) according to the KDOQI CKD classification. The eGFR was calculated in ml/min/1.73 m2 according to Schwartz formula . Graft function was also classified to CKD 1–5 stages.
Anthropometric features, clinical evaluation and medical data
In all participants, anthropometric features, personal and family history were evaluated; and a detailed physical examination was carried out. The body weight (BW) was measured to the nearest 0.1 kg using an electronic scale (SECA) and the height (Ht) to the nearest 0.1 cm by a wall stadiometer (Hyssna). BSA was calculated in m2.
The “dry weight” was also estimated in patients undergoing dialysis with the use of a body composition monitor. Body mass index (BMI) was calculated by the equation: BW (kg) per Ht (m2). Participants were classified as normal BMI, overweight (OW) and obese (OB) using the International growth charts . Moreover, standard deviation scores (SDS) for BW, Ht and BMI were calculated using a standardized age- and sex- specific calculator. Blood pressure (BP) was measured by an electronic automated oscillometric device Dynamap with a suitable cuff size (Critikon) for the child’s arm circumference. Three BP measurements (with one minute interval) were taken in a sitting position after a 5 min rest. The average of these measurements was used in the analysis. The systolic BP (SBP) and diastolic BP (DBP) values were classified using chart percentiles for age, sex and height and hypertension was defined as BP equal or above the 95th percentile . SDS for SBP and DBP were also calculated by a standardized calculator based on age, sex and height. A full cardiological evaluation was performed in all patients. Left ventricular mass (LVM) and left ventricular mass index (LVMI) were estimated.
Twelve out of 13 patients underwent conventional hemodialysis three times a week and one patient four times a week, approximately 4.5 h per session. The dialysis machines that were used were Gambro AK200S and Nikisso model dbb 05. Dialysers were chosen according to body surface area (BSA). In these subjects, BW, BMI and BP were re-evaluated after the completion of dialysis.
The mean duration of hemodialysis (HD) was 1.2 (SD 0.9) years. The mean duration of transplantation was 5.6 (SD 2.2) years. All RTR patients were on immunosuppressive drug treatment with prednisolone, mycophenolate and cyclosporine or tacrolimus.
Venous blood samples were collected between 8–9 am, after an overnight fast in all participants. All children were infection free for at least 10 days before the examination.
Biochemical parameters such as urea, creatinine, total protein, albumin, uric acid, electrolytes, transaminases and γGT were measured in serum using standard laboratory methods. Cystatin C was measured using an automated particle-enhanced nephelometric immunoassay (PENIA) on a Siemens Behring Nephelometer BN II system. Venous blood gases and a full blood count were obtained.
We defined anemia as levels of hemoglobin below the lowest limit of normal for age and sex. Metabolic acidosis was defined as pH <7.35 and base < 22 mmol/L.
For the determination of UII, whole venous blood in EDTA tubes was collected; it was immediately placed in ice and then centrifuged at 1600 g for 10 min at 4 °C. The supernatant was stored in aliquots of 200 μl at -70 °C until the time of analysis. Plasma UII levels were measured by a high sensitive enzyme immunoassay (EIA) kit (Phoenix Pharmaceuticals, Inc. 330 Beach Road, Burlinghame, CA 94010, USA) and expressed in ng/ml. The intra-assay and the inter-assay variation CV% were <5% and <14% respectively. The range was 0–100 ng/ml, the linear range 0.06–1.48 ng/ml, and the detection limit 0.06 ng/ml.
In patients undergoing hemodialysis the markers of renal function and plasma UII concentration were evaluated twice, before the initiation and after the completion of midweek dialysis session.
The Shapiro-Wilk test was performed to test for normal distribution of continuous variables. The results are given as mean (+/- SD) or as median and interquartile range (IQR) according to normality of relative frequencies. All qualitative variables are presented as absolute or relative frequencies.
The Student’s t-test or its non-parametric equivalent Mann-Whitney U test was used to compare continuous variables between the groups under study. The Fisher’s exact test was employed for comparison of categorical variables. One way analysis of variance (ANOVA) or Kruskal Wallis test was used for comparison of parametric and non-parametric variables between groups, respectively. Sidak correction was used for multiple comparisons.
Log transformed UII values were used as the dependent variable for the linear regression analysis and in multiple regression models in order to investigate the relationship between UII and a series of factors. Since log-transformed UII was used all interpretations are presented as proportion change in geometric mean of UII values.
Study groups and each one of the variables such as age, disease duration, markers of renal function (e.g. eGFR, creatinine, cystatin C and electrolytes) and hemodynamic parameters (SBP, DBP, heart rate, LVM and LVMI), were used as independent variables. The non parametric Spearman correlation coefficient was applied in order to associate UII levels with several factors.
All tests were two-tailed and statistical significance was established at p = 5%. Data were analyzed using STATA™ (Version 10.1 MP, Stata Corporation, College Station, TX, 77845, USA).
Clinical and anthropometric characteristics of patients
(n = 23)
(n = 14)
(n = 17)
Gender (Males %)
eGFR (ml/min/1.73 m2)
31.0 [22, 47]a
6.0 [6, 7]b
58.5 [47, 63]c
Disease duration (yrs)
-0.44 [-1.23, 0.62]a
-1.84 [-3.41, -0.86]b
0.41 [-0.37, 0.75]a
18.8 [16.9, 21.9]ab
15.9 [14.9, 18.4]a
21.7 [18.4, 26.7]b
0.41 [0.02, 1.2]ab
-0.70 [-1.29, 0.53]a
1.26 [0.61, 1.79]b
BMI (Increased %)
19.7 [14.7, 23.9]
13.7 [12.6, 19.3]
20.2 [15.6, 24.5]
Lean Body Mass (kg)
34.2 [20.3, 41.8]a
19 [17.7, 24.2]b
35.8 [25.9, 43.9]a
BMI-dry weight (kg/m2)
SDS-BMI (dry weight)
Systolic BP (mmHg)
SDS -Systolic BP
Diastolic BP (mmHg)
SDS- Diastolic BP
Increased BP (%)
Laboratory data of the patient groups
(n = 23)
(n = 14)
(n = 17)
78 [49, 128]a
162 [135, 203]b
47.5 [37, 66]c
1.7 [1.3, 2.3]a
7.4 [6.8, 9]b
1 [0.8, 1.2]c
1.85 [1.53, 3.25]a
6.54 [6.15, 6.96]b
1.42 [1.04, 1.67]c
Uric acid (mg/dl)
138 [137, 140]
137 [136, 139]
138 [137, 139]
4.6 [4.4, 5]ab
5 [4.7, 5.5]a
4.4 [4.2, 4.7]b
103 [101, 104]ac
97.5 [91.5, 99]b
104 [102, 108]c
9.9 [9.7 , 10.2]
10.1 [9.7, 10.3]
10 [9.7, 10.3]
4.4 [4.1, 4.9]
5 [4.5, 6.9]
4.1 [4.0, 4.3]
22 [18, 28]
18 [17, 23]
17.5 [17, 19]
14 [12, 21]
16 [12, 24]
13.5 [11, 16]
12 [10, 14]
12 [8, 48]
12 [10, 16]
Total Protein (g/dl)
Acidosis (Yes %)
Anemia (Yes %)
Comparisons between patient groups and controls for UII and log-transformed UII values
(n = 23)
(n = 14)
(n = 17)
(n = 117)
3.53 [2.49, 4.46]a
2.42 [1.60, 2.79]ab
4.16 [2.53, 6.96]a
1.28 [1.08, 1.63]b
Log - Urotensin II
Finally, in HD patients UII and log-transformed UII were increased significantly after the completion of dialysis [2.42 (1.6–2.79) vs 4.38 (2.17–7.62), p = 0.043 and 0.71 (SD 0.53) vs 1.45 (SD 0.96), p = 0.022 respectively) and there was no significant difference compared to other patient groups. Moreover, an increase of approximately 197% in the mean of U II scores is observed (p < 0.05) when switching from controls to HD patients measured at the end of their dialysis session. There was no correlation found between BW, Dry BW and their SDS with UII levels before and after the completion of dialysis. Furthermore, the increase of UII did not correlate with the decrease of body weight (p = 0.640), the improvement of renal function and the decrease of blood pressure.
There was no statistically significant difference in log-UII levels according to sex, age and body mass index in patients and controls.
UII levels in patients were negatively correlated with serum creatinine (r -0.37, p = 0.006) and cystatin C (r -0.44, p = 0.001). In addition, Spearman’s correlation coefficient was applied for the same pairs of factors per group. No statistical significant association was detected between any pair of factors (p > 0.05). For this reason, CKD and HD were merged, resulting in a significant negative correlation of UII with creatinine (r -0.46, p = 0.004) and cystatin C (r -0.41, p = 0.001) and a positive one with serum albumin levels (r 0.36, p = 0.032).
Linear regression analysis of log-UT II adjusted for pH, HCO3 and metabolic acidosis by group*
Linear regression analysis of log-UT II adjusted for LVMI, LVM and Heart Rate by group*
The current study indicates that children and adolescents with CKD, especially patients who underwent renal transplantation and patients with no dialysed CKD, have significantly higher plasma urotensin II (UII) levels compared to healthy controls. Moreover, plasma UII concentration was significantly increased at the end of the HD session and was similar to that of RTR and CKD patients and higher than healthy controls. The only factor that seems to affect significantly plasma UII levels is the presence of metabolic acidosis. The effect of left ventricular mass (LVM) in UII levels was of marginal significance.
Plasma UII levels have hardly been studied in children and adolescents with renal diseases. A study in children with minimal change nephrotic syndrome revealed that plasma UII levels were lower and urinary UII levels were higher in relapse than those in remission. This difference was attributed to proteinuria. Moreover, patients, in relapse and in remission, had lower plasma and urine UII concentrations compared to healthy controls. Plasma UII had a strong correlation with plasma albumin, only in remission . More dense UII immunoreactivity in renal biopsy specimens of children with membranoproliferative glomerulonephritis compared to healthy kidneys has been found and a possible autocrine/paracrine function of UII in kidneys has been considered .
To our knowledge there are no studies of plasma UII in children and adolescents with chronic kidney disease or in renal transplant recipients.
A few studies have evaluated plasma UII levels in adults with CKD or ESKD on HD and only one in RTR adults. The contradictory results of these studies may be mainly due to different methodology such as the heterogeneous populations of patients and controls, and the assays used for the determination of UII levels.
The first study of plasma UII-like immunoreactivity in adults with CKD was published fourteen years ago . Plasma UII levels were higher in patients with CKD, especially those with ESKD on HD, compared to controls, although UII levels did not correlate with serum creatinine. Contrary to our study no significant change of UII levels at the end of the HD session was noted. Totsune et al assumed that increased UII may be the result of the decreased excretion from the kidney or of increased production. In addition, it was found that mRNA encoding UII precursor and its receptor was expressed not only in renal but also in many other tissues such as in the heart . Three years later the same authors reported 1.6 times higher plasma UII levels in diabetic patients with severe CKD compared to patients with mild to moderate CKD. Furthermore, patients with more severe disease had 1.8 times higher urinary UII excretion than healthy controls .
Twofold higher plasma UII levels were found in patients with ESKD on hemodialysis (HD) compared to healthy controls in another study. Moreover, UII was an independent, inverse predictor of cardiovascular (CV) events in those patients . An inverse correlation has also been observed between UII and some biomarkers of atherosclerosis and endothelial activation in ESKD patients undergoing HD. Furthermore, UII levels were lower in patients who received antihypertensive medication . However, it remains unclear whether the hypertensive treatment or the hypertension influences UII levels . A negative association between UII and CV stress hormones such as norepinephrine and brain natriuretic peptide (BNP) in patients on HD has also been considered, suggesting that higher UII concentration may be vasculoprotective . The results of all the above mentioned studies contradict previous ones in which a positive correlation between increased UII and cardiovascular diseases was reported [31, 32]. A direct association of circulating UII with left ventricular systolic function and an inverse association with left atrial volume were considered, by Zoccali et al. , in the same patients recorded by Mallamaci F et al. . These data further support the hypothesis that high UII is cardioprotective in adult ESKD patients.
Similarly, UII concentration was inversely correlated with the history of CV events as well with a lower risk of death from CV or other causes in adults with earlier stages of CKD .
Higher urinary UII-like immunoreactivity was found in hypertensive adults with normal renal function compared to controls. Furthermore, the hypertensive patients with renal disease had higher urinary UII-like immunoreactivity than normotensive patients with renal disease . Greater plasma UII concentration in hypertensive compared to normotensive subjects has also been considered . Increased expression of UII-related peptide and its receptor’s mRNAs in the kidneys of rats with hypertension and chronic kidney failure has been established .
Contrary to other studies, Mosenkis A et al., showed lower UII concentrations mainly in CKD as well in ESRD patients than controls. UII was negatively correlated with serum creatinine and the stage of CKD and positively with creatinine clearance. However the authors noticed an increase in UII levels at the end of the HD session . Furthermore, in a recent study, predialysis of UII levels were lower in overhydrated compared to normohydrated ESKD patients . Taking into consideration previous reports on the relationship between low UII concentration and the risk of cardiovascular events in patients with CKD, the authors assume that low levels may be a therapeutic target in overhydrated CKD patients .
It is speculated, that the removal of fluids from our patients by HD and the resulting hemoconcentration may have a role in the increase of HDII levels after the completion of HD [36, 37]. Moreover, UII is a middle size molecule (molecular mass = 1388.6 g/mol) and is only partially removed using the convential HD [36, 38]. In addition, the removal of fluids which leads to a reduction in blood pressure and to the improvement of many biochemical parameters, may have as a result an increased production of UII by the heart or other tissues [9, 36].
According to our results, there was no significant correlation found between UII and blood pressure measurements. These results agree with Mosenkis et al., who considered that this might be due to antihypertensive treatment .
Another recent study evaluated, for the first time, plasma UII levels in adults with RTR. The authors found significantly higher UII levels in RTR compared to CKD and to healthy controls.. This could not be explained solely by the transplanted kidney, because UII levels were higher than healthy controls and It was assumed that this could be immunosuppressive drug-related. However, the immunosuppressive drug doses and the duration of transplantation did not correlate with UII levels . In our study, RTR children had significantly higher UII levels compared to healthy controls and higher but without statistical significance UII levels than CKD patients. There was also no correlation between UII and the duration of renal transplantation. We cannot support that immunosuppressive treatment was responsible for higher UII concentration of RRT patients, because of the small number of participants.
Another finding of our study was the correlation between UII and metabolic acidosis. The increase of pH was associated with a decrease of UII which was independent from all other parameters. There are no studies evaluating the correlation between these two markers. A study in human smooth muscle cells showed that UII affected intracellular pH inducing acidosis . The high percentage of RTR patients with metabolic acidosis might be immunosuppressive drug-related . A correlation of metabolic acidosis and protein catabolism is documented in a number of studies [42–44]. Protein catabolism might trigger the increase of UII.
UII levels did not differ significantly between males and females of this study and did not correlate with age in patients and controls. This is in accordance with most of the above mentioned studies [9, 36, 45]. On the contrary, a significant correlation between age and UII has been reported  and Hurshitoglu et al  observed that males tended to have higher levels of UII than females.
The main limitations of this study is the small number of participants per group and the absence of repeated measurements of UII after a certain period of time.
Children and adolescents with chronic kidney disease, as well as renal transplant recipients, have significantly higher urotensin II levels than healthy controls. This could not be attributed solely to renal failure, since renal transplanted subjects had higher levels than healthy controls, non dialyzed CKD and HD patients. The effect of immunosuppressive therapy may play a role for these findings. The increase of urotensin II concentration at the end of the HD session might be the result of the correction of overhydration, the changes in biochemical and clinical parameters as well as the use of conventional hemodialysis.
Larger prospective studies of children with renal disease are required in order to establish plasma urotensin II levels and clarify its importance regarding the evaluation, follow up and management of these patients.
Body mass index
Body surface area
Chronic kidney disease
Diastolic blood pressure
estimated Glomerular Filtration Rate
End-stage kidney disease
Left ventricular mass
Left ventricular mass index
Renal transplant recipients
Systolic blood pressure
Standard deviation scores
Availability of data and materials
The data and materials of the study can be requested from the corresponding author.
AG: designed the study, followed its evolution, evaluated and processed the results, contributed to statistical analyses and prepared the manuscript. SD: contributed to the study design, patient recruitment, clinical examination, sample and data collection, statistical analyses and manuscript’s preparation. AM: carried out the measurement of plasma Urotensin II levels and contributed to the preparation of the manuscript. VA: contributed to patient recruitment, data collection, and manuscript preparation. AM: contributed to patient recruitment, clinical examination and data collection. MM: contributed to patient recruitment, clinical examination, and sample and data collection. GG: carried out the cardiological examination of participants and evaluated the findings. DG: conducted the cardiological examination of children and evaluated the findings. CS: contributed to the study design, evaluation and processing of the results, and manuscript preparation. DG: contributed to the study design, investigation of plasma Urotensin II, evaluation of the results, and preparation of the manuscript. All authors have approved the manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
The study was conducted from May 2012 to February 2014 and was approved by the Hospital’s Ethics Committee prior to its initiation. All participants’ parents or legal guardians were required to complete a consent form.
The authors declare no conflict of interest. The manuscript was not published elsewhere.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, et al. It is a potent vasoconstrictor and agonist for the orphan recepror GPR14. Nature. 1999;401:282–6.View ArticlePubMedGoogle Scholar
- Bottrill FE, Douglas SA, Hiley CR, White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol. 2000;130:1865–70.View ArticlePubMedPubMed CentralGoogle Scholar
- Affolter J, Webb DJ. Urotensin II; a new mediator in cardiopulmonary regulation? Lancet. 2001;358:774–5.View ArticlePubMedGoogle Scholar
- Charles CJ, Rademaker MT, Richards AM, Yandle TG. Urotensin II: Evidence for cardiac, hepatic and renal production. Peptides. 2005;26:2211–4.View ArticlePubMedGoogle Scholar
- Mosenkis A, Danoff TM, Aiyar N, Bazeley J, Townsend RR. Human urotensin II in the plasma of anephric subjects. Nephrol Dial Transplant. 2007;22:1269–70.View ArticlePubMedGoogle Scholar
- Cheung BM, Leung R, Wong LY. Plasma concentration of urotensin II is raised in hypertension. J Hypertens. 2004;22(7):1341–4.View ArticlePubMedGoogle Scholar
- Heller J, Schepke M, Neef M, Woitas R, Rabe C, Sauerbrunch T. Increased Urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol. 2002;37(6):767–72.View ArticlePubMedGoogle Scholar
- Richards AM, Nicholls MG, Lainchbury JG, Fisher S, Yandle TG. Plasma Urotensin II in heart failure. Lancet. 2002;360:545–6.View ArticlePubMedGoogle Scholar
- Totsune K, Takahashi K, Arihara Z, Sone M, Satoh F, Ito S, et al. Role of Urotensin II in patients on dialysis. Lancet. 2001;358:810–1.View ArticlePubMedGoogle Scholar
- Totsune K, Takahashi K, Arihara Z, Sone M, Murakami O, Ito S, et al. Elevated plasma levels of immunoreactivity urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides. 2004;25:1809–14.View ArticlePubMedGoogle Scholar
- Zoccali C, Mallamaci F. Urotensin II: a cardiovascular and renal update. Curr Opin Nephrol Hypertens. 2008;17(2):199–204.View ArticlePubMedGoogle Scholar
- Balat A, Buyukcelik M. Urotensin-II: More than a mediator for kidney. Int J Nephrol 2012; 249790. doi:10.1155/2012/249790
- Krum H, Kemp W. Therapeutic potential of blockade of the Urotensin II system in systemic hypertension. Curr Hypertens Rep. 2007;9(1):53–8.View ArticlePubMedGoogle Scholar
- Ashton N. Renal and vascular actions of urotensin II. Kidney Intern. 2006;70:624–9.View ArticleGoogle Scholar
- Khan SQ, Bhandari SS, Quinn P, Davies JE, Ng LL. Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. Int J Cardiol. 2007;117(3):323–8.View ArticlePubMedGoogle Scholar
- Takahashi K, Hirose T, Mori N, Morimoto R, Kohzuki M, Imai Y, et al. The renin-angiotensin system, adrenomedullins and urotensin II in the kidney: possible renoprotection via the kidney peptide systems. Peptides. 2009;30:1575–85.View ArticlePubMedGoogle Scholar
- Zoccali C, Mallamaci F, Tricepi G, Cutrupi S, Pizzini P, Malatino L. Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease. Kidney Int. 2006;69:1253–8.View ArticlePubMedGoogle Scholar
- Ravani P, Tripepi G, Pecchini P, Mallamaci F, Malberti F, Zoccali C. Urotensin II is an inverse predictor of death and fatal cardiovascular events in chronic kidney disease. Kidney Int. 2008;73(1):95–101.View ArticlePubMedGoogle Scholar
- Wang T, Li SX, Zhang XQ, Gu XH, Song Y, Zhang G, et al. Study on the effect of adrenomedulin and urotensin-II on pulmonary hypertension of patients with congenital heart disease. Zhonghua Yi Xue Za Zhi. 2005;85(38):2691–5.PubMedGoogle Scholar
- Pawar R, Kemp W, Roberts S, Krum H, Yandle T, Hardikar W. Urotensin II levels are an important marker for the severity of portal hypertension in children. J Pediatr Gastroenterol Nutr. 2011;53(1):88–92.View ArticlePubMedGoogle Scholar
- Simpson CM, Penny DJ, Stocker CF, Shekerdemian LS. Urotensin II is raised in children with congenital heart disease. Heart. 2006;92:983–4.View ArticlePubMedPubMed CentralGoogle Scholar
- Balat A, Pakir IH, Gok F, Anarat R, Sahinoz S. Urotensin II levels in children with minimal change nephrotic syndrome. Pediatr Nephrol. 2005;20:42–5.View ArticlePubMedGoogle Scholar
- Balat A, Karakok M, Yilmaz K, Kibar Y. Urotensin-II Immunoreactivity in Children with Chronic Glomerulonephritis. Ren Fail. 2007;29:573–8.View ArticlePubMedGoogle Scholar
- Hogg JR, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, et al. National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative Clinical Practice Guidelines for Chronic Kidney Disease in Children and Adolescents: Evaluation, Classification and Stratification. Pediatrics. 2003;111(6):1416–21.View ArticlePubMedGoogle Scholar
- Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009;4(11):1832–43.View ArticlePubMedGoogle Scholar
- Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide:international survey. BMJ. 2000;320:1240–3.View ArticlePubMedPubMed CentralGoogle Scholar
- Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011; 128 (Suppl 5): S213-256.
- Mallamaci F, Cutrupi S, Pizzini P, Tripepi G, Zoccali C. Urotensin iI and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease. Am J Hypertens. 2006;19:505–10.View ArticlePubMedGoogle Scholar
- Boos CJ, Lip GY. Urotensin and cardiovascular risk among patients with end-stage renal disease: fact or fiction? Am J Hypertens. 2006;19(5):511–2.View ArticlePubMedGoogle Scholar
- Mallamaci F, Cutrupi S, Pizzini P, Tripepi G, Zoccali C. Urotensin in end- stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides. J Nephrol. 2005;18:727–32.PubMedGoogle Scholar
- Thanassoulis G, Huyhn T, Giaid A. Urotensin II and cardiovascular diseases. Peptides. 2004;25:1789–94.View ArticlePubMedGoogle Scholar
- Richards AM, Charles C. Urotensin II in the cardiovascular system. Peptides. 2004;25:1795–802.View ArticlePubMedGoogle Scholar
- Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Pizzini P, Cutrupi S, et al. Urotensin II and Cardiomyopathy in End- Stage Renal Disease. Hypertension. 2008;51:326–33.View ArticlePubMedGoogle Scholar
- Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N, et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertension. 2001;19:2185–90.View ArticleGoogle Scholar
- Mori N, Hirose T, Nakayama T, Ito O, Kanazawa M, Imai Y, et al. Increased expression of urotensin II-related peptide and its receptor in kidney hypertension or renal failure. Peptides. 2009;30:400–8.View ArticlePubMedGoogle Scholar
- Mosenkis A, Kallem RR, Danoff TM, Aiyar N, Bazeley J, Townsend RR. Renal impairment, hypertension and plasma urotensin II. Nephrol Dial Transplant. 2011;26:609–14.View ArticlePubMedGoogle Scholar
- Yilmaz B, Yilmaz A, Sari F, Sarikaya AM, Ellidag HY, Kucukseymen S, Ozpelit E. Decrease of Urotensin II activity can impact on the volume status in predialysis chronic kidney disease. Ren Failure. 2015;37(3):476–81.View ArticleGoogle Scholar
- Pierratos A. New Approaches to hemodialysis. Annu Rev Med. 2004;55:179–89.View ArticlePubMedGoogle Scholar
- Hursitoglu M, Tukek T, Cikrikcioglu MA, Kara O, Kazancioglu R, Ozkan O, et al. Urotensin II levels in patients with chronic kidney disease and kidney transplants. Upsala J of Med Sciences. 2012;117:22–7.View ArticleGoogle Scholar
- Tsai YT, Lee CY, Hsu CC, Chang CY, Hsueh MK, Huang EY, et al. Effects of urotensin II on intracellular pH regulation in cultured human internal mammary artery smooth muscle cells. Peptides. 2014;56:173–82.View ArticlePubMedGoogle Scholar
- Tanrisev M, Gungor O, Kocyigit I, Kurtulmus Y, Tugmen C, Colak H, et al. Renal tubular acidosis in renal transplant patients: the effect of immunosuppressive drugs. Ann Transplant. 2015;20:85–91.View ArticlePubMedGoogle Scholar
- Papadoyannakis NJ, Stefanidis CJ, McGeown M. The effect of the correction of metabolic acidosis on nitrogen and potassium balance of patients with chronic renal failure. Am J Clin Nutr. 1984;40(3):623–7.PubMedGoogle Scholar
- Mitch WE, Medina R, Grieber S, May RC, England BK, Price SR, Bailey JL, Goldberg AL. Metabolic acidosis stimulates muscle protein degradation by activating the adenosine triphosphate-dependent pathway involving ubiquitin and proteasomes. J Clin Invest. 1994;93(5):2127–33.View ArticlePubMedPubMed CentralGoogle Scholar
- Kraut JA, Madias NE. Consequences and therapy of the metabolic acidosis of chronic kidney disease. Pediatr Nephrol. 2011;26(1):19–28.View ArticlePubMedGoogle Scholar
- Ng LL, Loke I, O’Brien RJ, Squire IB, Davies JE. Plasma urotensin in human systolic heart failure. Circulation. 2002;106:2877–80.View ArticlePubMedGoogle Scholar